Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/93004
標題: Effects of Topical Lactoferrin, Platelet-Rich plasma and Autologous Serum on Corneal Epithelial Healing in Rabbits
乳鐵蛋白、血小板濃厚血漿與自體血清眼藥水對於兔角膜上皮癒合之影響
作者: Hsin-Yu Chen
陳欣佑
關鍵字: 乳鐵蛋白
血小板濃厚血漿
角膜潰瘍
lactoferrin
platelet-rich plasma
corneal ulcer
引用: Åbrink M, Larsson E, Gobl A, et al. Expression of lactoferrin in the kidney: implications for innate immunity and iron metabolism. Kidney International 2000;57:2004-2010. Adlerova L, Bartoskova A, Faldyna M. Lactoferrin: a review. Veterinarni Medicina 2008;53:457-468. Aghaloo TL, Moy PK, Freymiller EG. Investigation of platelet-rich plasma in rabbit cranial defects: a pilot study. Journal of Oral and Maxillofacial Surgery 2002;60:1176-1181. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunology Letters 2003;85:85-95. Aldavood S, Behyar R, Sarchahi A, et al. Effect of acetylcysteine on experimental corneal wounds in dogs. Ophthalmic Research 2003;35:319-323. Alio JL, Abad M, Artola A, et al. Use of autologous platelet-rich plasma in the treatment of dormant corneal ulcers. Ophthalmology 2007a;114:1286-1293. Alio JL, Colecha JR, Pastor S, et al. Symptomatic dry eye treatment with autologous platelet-rich plasma. Ophthalmic Research 2007b;39:124-129. Alio JL, Rodriguez AE, Martinez LM, et al. Autologous fibrin membrane combined with solid platelet-rich plasma in the management of perforated corneal ulcers: a pilot study. JAMA Ophthalmology 2013;131:745-751. Altmann S, Emanuel A, Toomey M, et al. A quantitative rabbit model of vaccinia keratitis. Investigative Ophthalmology & Visual Science 2010;51:4531-4540. Andersen JH, Jenssen H, Gutteberg TJ. Lactoferrin and lactoferricin inhibit Herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir. Antiviral Research 2003;58:209-215. Andia I, Abate M. Platelet-rich plasma: underlying biology and clinical correlates. Regenerative Medicine 2013;8:645-658. Anitua E, Andia I, Ardanza B, et al. Autologous platelets as a source of proteins for healing and tissue regeneration. Thrombosis and Haemostasis 2004;91:4-15. Anitua E, Orive G, Pla R, et al. The effects of PRGF on bone regeneration and on titanium implant osseointegration in goats: a histologic and histomorphometric study. Journal of Biomedical Materials Research Part A 2009;91:158-165. Anitua E, Prado R, Sánchez M, et al. Platelet-rich plasma: preparation and formulation. Operative Techniques in Orthopaedics 2012;22:25-32. Anitua E, Muruzabal F, Alcalde I, et al. Plasma rich in growth factors (PRGF-Endoret) stimulates corneal wound healing and reduces haze formation after PRK surgery. Experimental eye research 2013a;115:153-161. Anitua E, Muruzabal F, Pino A, et al. Biological stability of plasma rich in growth factors eye drops after storage of 3 months. Cornea 2013b;32:1380-1386. Anitua E, de la Fuente M, Muruzabal F, et al. Plasma rich in growth factors (PRGF) eye drops stimulates scarless regeneration compared to autologous serum in the ocular surface stromal fibroblasts. Experimental Eye Research 2015a;135:118-126. Anitua E, Muruzabal F, Tayebba A, et al. Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies. Acta Ophthalmologica: doi:10.1111/aos.12710, 2015b. (Available at: http://onlinelibrary.wiley.com/doi/ 10.1111/aos.12710/full) Araújo LU, Grabe-Guimarães A, Mosqueira VCF, et al. Profile of wound healing process induced by allantoin. Acta Cirurgica Brasileira 2010;25:460-466. Arnold RR, Russell JE, Champion WJ, et al. Bactericidal activity of human lactoferrin: influence of physical conditions and metabolic state of the target microorganism. Infection and Immunity 1981;32:655-660. Arnold RR, Russell JE, Champion WJ, et al. Bactericidal activity of human lactoferrin: differentiation from the stasis of iron deprivation. Infection and Immunity 1982;35:792-799. Ashby B, Garrett Q, Willcox M. Bovine lactoferrin structures promoting corneal epithelial wound healing in vitro. Investigative Ophthalmology & Visual Science 2011;52:2719-2726. Avila MY. Restoration of human lacrimal function following platelet-rich plasma injection. Cornea 2014;33:18-21. Baker EN, Baker HM. A structural framework for understanding the multifunctional character of lactoferrin. Biochimie 2009;91:3-10. Balasubramanian SA, Pye DC, Willcox MDP. Levels of lactoferrin, secretory IgA and serum albumin in the tear film of people with keratoconus. Experimental Eye Research 2012;96:132-137. Ballow M, Donshik PC, Rapacz P, et al. Tear lactoferrin levels in patients with external inflammatory ocular disease. Investigative Ophthalmology & Visual Science 1987;28:543-545. Barletta JP, Angella G, Balch KC, et al. Inhibition of pseudomonal ulceration in rabbit corneas by a synthetic matrix metalloproteinase inhibitor. Investigative Ophthalmology & Visual Science 1996;37:20-28. Baveye S, Elass E, Fernig DG, et al. Human lactoferrin interacts with soluble CD14 and inhibits expression of endothelial adhesion molecules, E-selectin and ICAM-1, induced by the CD14-lipopolysaccharide complex. Infection and Immunity 2000a;68:6519-6525. Baveye S, Elass E, Mazurier J, et al. Lactoferrin inhibits the binding of lipopolysaccharides to L-selectin and subsequent production of reactive oxygen species by neutrophils. FEBS letters 2000b;469:5-8. Bellamy W, Takase M, Yamauchi K, et al. Identification of the bactericidal domain of lactoferrin. Biochimica et Biophysica Acta 1992;1121:130-136. Bellamy W, Wakabayashi H, Takase M, et al. Killing of Candida albicans by lactoferricin B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrin. Medical Microbiology and Immunology 1993;182:97-105. Bezault J, Bhimani R, Wiprovnick J, et al. Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Research 1994;54:2310-2312. Blais DR, Vascotto SG, Griffith M, et al. LBP and CD14 secreted in tears by the lacrimal glands modulate the LPS response of corneal epithelial cells. Investigative Ophthalmology & Visual Science 2005;46:4235-4244. Bonini S, Lambiase A, Rama P, et al. Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology 2000;107:1347-1351. Botella AJ, Peiró JFM, Márques K, et al. Effectiveness of 100% autologous serum drops in ocular surface disorders. Farmacia Hospitalaria 2011;35:8-13. Bourcier T, Thomas F, Borderie V, et al. Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases. British Journal of Ophthalmology 2003;87:834-838. Bourcier T, Acosta MC, Borderie V, et al. Decreased corneal sensitivity in patients with dry eye. Investigative Ophthalmology & Visual Science 2005;46:2341-2345. Bremond-Gignac D, Chiambaretta F, Milazzo S. A European perspective on topical ophthalmic antibiotics: current and evolving options. Ophthalmology and Eye Diseases 2011;3:29-43. Britigan BE, Lewis TS, Waldschmidt M, et al. Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells. The Journal of Immunology 2001;167:2921-2928. Brock JH. The physiology of lactoferrin. Biochemistry and Cell Biology 2002;80:1-6. Browning AC, Shah S, Dua HS, et al. Alcohol debridement of the corneal epithelium in PRK and LASEK: an electron microscopic study. Investigative Ophthalmology & Visual Science 2003;44:510-513. Calonge M, Enríquez-de-Salamanca A, Diebold Y, et al. Dry eye disease as an inflammatory disorder. Ocular Immunology and Inflammation 2010;18:244-253. Caccavo D, Pellegrino NM, Altamura M, et al. Antimicrobial and immunoregulatory functions of lactoferrin and its potential therapeutic application. Journal of Endotoxin Research 2002;8:403-417. Cervelli V, Gentile P, Scioli MG, et al. Application of platelet-rich plasma in plastic surgery: clinical and in vitro evaluation. Tissue Engineering Part C 2009;15:625-634. Chen HJ, Pires RTF, Tseng SCG. Amniotic membrane transplantation for severe neurotrophic corneal ulcers. British Journal of Ophthalmology 2000;84:826-833. Cirioni O, Giacometti A, Barchiesi F, et al. Inhibition of growth of Pneumocystis carinii by lactoferrins alone and in combination with pyrimethamine, clarithromycin and minocycline. Journal of Antimicrobial Chemotherapy 2000;46:577-582. Conesa C, Calvo M, Sánchez L. Recombinant human lactoferrin: a valuable protein for pharmaceutical products and functional foods. Biotechnology Advances 2010;28:831-838. Congdon NG, Schein OD, von Kulajta P, et al. Corneal complications associated with topical ophthalmic use of nonsteroidal antiinflammatory drugs. Journal of Cataract & Refractive Surgery 2001;27:622-631. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999;284:1318-1322. Cowell BA, Willcox MDP, Schneider RP. Growth of gram‐negative bacteria in a simulated ocular environment. Australian and New Zealand Journal of Ophthalmology 1997;25:S23-S26. Cramer E, Pryzwansky KB, Villeval JL, et al. Ultrastructural localization of lactoferrin and myeloperoxidase in human neutrophils by immunogold. Blood 1985;65:423-432. Crouch S, Slater K, Fletcher J. Regulation of cytokine release from mononuclear cells by the iron-binding protein lactoferrin. Blood 1992;80:235-240. Damiens E, El Yazidi I, Mazurier J, et al. Role of heparan sulphate proteoglycans in the regulation of human lactoferrin binding and activity in the MDA-MB-231 breast cancer cell line. European Journal of Cell Biology 1998;77:344-351. Das S, Seitz B. Recurrent corneal erosion syndrome. Survey of Ophthalmology 2008;53:3-15. Davidsson L, Kastenmayer P, Yuen M, et al. Influence of lactoferrin on iron absorption from human milk in infants. Pediatric Research 1994;35:117-124. Davies NM. Biopharmaceutical considerations in topical ocular drug delivery. Clinical and Experimental Pharmacology and Physiology 2000;27:558-562. Damiens E, Mazurier J, El Yazidi I, et al. Effects of human lactoferrin on NK cell cytotoxicity against haematopoietic and epithelial tumour cells. Biochimica et Biophysica Acta 1998;1402:277-287. Damiens E, El Yazidi I, Mazurier J, et al. Lactoferrin inhibits G1 cyclin‐dependent kinases during growth arrest of human breast carcinoma cells. Journal of Cellular Biochemistry 1999;74:486-498. de Leon JM, Driver VR, Fylling CP, et al. The clinical relevance of treating chronic wounds with an enhanced near-physiological concentration of platelet-rich plasma gel. Advances in Skin & Wound Care 2011;24:357-368. del Castillo JMB, de la Casa JMM, Sardina RC, et al. Treatment of recurrent corneal erosions using autologous serum. Cornea 2002;21:781-783. Dial EJ, Lichtenberger LM. Effect of lactoferrin on Helicobacter felis induced gastritis. Biochemistry and Cell Biology 2002;80:113-117. Diez-Feijóo E, Grau AE, Abusleme EI, et al. Clinical presentation and causes of recurrent corneal erosion syndrome: review of 100 patients. Cornea 2014;33:571-575. Digumarti R, Wang Y, Raman G, et al. A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer. Journal of Thoracic Oncology 2011;6:1098-1103. Dursun D, Kim MC, Solomon A, et al. Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids. American Journal of Ophthalmology 2001;132:8-13. Dzitko K, Dziadek B, Dziadek J, et al. Toxoplasma gondii: inhibition of the intracellular growth by human lactoferrin. Polish Journal of Microbiology 2007;56:25-32. Edelhauser HF. The balance between corneal transparency and edema the proctor lecture. Investigative Ophthalmology & Visual Science 2006;47:1755-1767. Ehrenfest DMD, Sammartino G, Shibli JA, et al. Guidelines for the publication of articles related to platelet concentrates (platelet-rich plasma-PRP, or platelet-rich fibrin-PRF): the international classification of the POSEIDO. The Periodontology, Oral Surgery, Esthetic and Implant Dentistry Organization Journal 2013;1:17-27. Elass E, Masson M, Mazurier J, et al. Lactoferrin inhibits the lipopolysaccharide- induced expression and proteoglycan-binding ability of interleukin-8 in human endothelial cells. Infection and Immunity 2002;70:1860-1866. Elass-Rochard E, Legrand D, Salmon V, et al. Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein. Infection and Immunity 1998;66:486-491. Ellenberg D, Azar DT, Hallak JA, et al. Novel aspects of corneal angiogenic and lymphangiogenic privilege. Progress in Retinal and Eye Research 2010;29:208-248. Ellison RT, Giehl TJ, LaForce FM. Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin. Infection and Immunity 1988;56:2774-2781. Ellison RT, Giehl TJ. Killing of gram-negative bacteria by lactoferrin and lysozyme. Journal of Clinical Investigation 1991;88:1080-1091. Eming SA, Krieg T, Davidson JM. Inflammation in wound repair: molecular and cellular mechanisms. Journal of Investigative Dermatology 2007;127:514-525. Engelmayer J, Blezinger P, Varadhachary A. Talactoferrin stimulates wound healing with modulation of inflammation. Journal of Surgical Research 2008;149:278-286. Enríquez-de-Salamanca A, Castellanos E, Stern ME, et al. Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. Molecular Vision 2010;16:862-873. Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plastic and Reconstructive Surgery 2004;114:1502-1508. Fairweather-Tait SJ, Balmer SE, Scott PH, et al. Lactoferrin and iron absorption in newborn infants. Pediatric Research 1987;22:651-654. Featherstone HJ and Heinrich CL. The Eye Examination and diagnostic procedures. In: Gelatt KN, Gilger BC, Kern TJ, eds. Veterinary Ophthalmology. 5th ed. Iowa: John Wiley & Sons Inc., 2013;533-613. Fischer R, Debbabi H, Dubarry M, et al. Regulation of physiological and pathological Th1 and Th2 responses by lactoferrin. Biochemistry and Cell Biology 2006;84:303-311. Fini ME, Cook JR, Mohan R. Proteolytic mechanisms in corneal ulceration and repair. Archives of Dermatological Research 1998;290:S12-S23. Flach AJ. Corneal melts associated with topically applied nonsteroidal anti-inflammatory drugs. Transactions of the American Ophthalmological Society 2001;99:205-210. Flanagan JL, Willcox MDP. Role of lactoferrin in the tear film. Biochimie 2009;91:35-43. Foster TE, Puskas BL, Mandelbaum BR, et al. Platelet-rich plasma from basic science to clinical applications. The American Journal of Sports Medicine 2009;37:2259-2272. Fox RI, Chan R, Michelson JB, et al. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis & Rheumatism 1984;27:459-461. Fréchette JP, Martineau I, Gagnon G. Platelet-rich plasmas: growth factor content and roles in wound healing. Journal of Dental Research 2005;84:434-439. Galasso O, Mariconda M, Romano G, et al. Expandable intramedullary nailing and platelet rich plasma to treat long bone non-unions. Journal of Orthopaedics and Traumatology 2008;9:129-134. Gao J, Gelber-Schwalb TA, Addeo JV, et al. Apoptosis in the rabbit cornea after photorefractive keratectomy. Cornea 1997;16:200-208. Geerling G, Maclennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. British Journal of Ophthalmology 2004;88:1467-1474. Gehring S, Hoerauf H, Laqua H, et al. Preparation of autologous platelets for the ophthalmologic treatment of macular holes. Transfusion 1999;39:144-148. Ghaffarpasand F, Dehghankhalili M, Shahrezaei M. Platele rich plasma for traumatic non-union fractures: a novel but controversial bone regeneration strategy. Bulletin of Emergency And Trauma 2013;1:99-101. Gokhale NS. Medical management approach to infectious keratitis. Indian Journal of Ophthalmology 2008;56:215-220. González-Chávez SA, Arévalo-Gallegos S, Rascón-Cruz Q. Lactoferrin: structure, function and applications. International Journal of Antimicrobial Agents 2009;33:301.e1-301.e8. Gordon JF, Johnson P, Musch DC, et al. Topical fibronectin ophthalmic solution in the treatment of persistent defects of the corneal epithelium. American Journal of Ophthalmology 1995;119:281-287. Gönül B, Koz M, Ersöz G, et al. Effect of EGF on the corneal wound healing of alloxan diabetic mice. Experimental Eye Research 1992;54:519-524. Grierson I, Heathcote L, Hiscott P, et al. Hepatocyte growth factor/scatter factor in the eye. Progress in Retinal and Eye Research 2000;19:779-802. Guidera AC, Luchs JI, Udell IJ. Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology 2001;108:936-944. Gum GG, MacKay EO. Physiology of the eye. In: Gelatt KN, Gilger BC, Kern TJ, eds. Veterinary Ophthalmology. 5th ed. Iowa: John Wiley & Sons Inc., 2013;171-207. Guillen C, McInnes IB, Vaughan D, et al. The effects of local administration of lactoferrin on inflammation in murine autoimmune and infectious arthritis. Arthritis & Rheumatism 2000;43:2073-2080. Haber M, Cao Z, Panjwani N, et al. Effects of growth factors (EGF, PDGF‐BB and TGF‐β1) on cultured equine epithelial cells and keratocytes: implications for wound healing. Veterinary Ophthalmology 2003;6:211-217. Hartwig D, Härtel C, Hennig H, et al. Evidence for de novo synthesis of cytokines and chemokines in platelet concentrates. Vox sanguinis 2002;82:182-190. Hayes TG, Falchook GF, Varadhachary GR, et al. Phase I trial of oral talactoferrin alfa in refractory solid tumors. Investigational New Drugs 2006;24:233-240. Hayes TG, Falchook GS, Varadhachary A. Phase IB trial of oral talactoferrin in the treatment of patients with metastatic solid tumors. Investigational New Drugs 2010;28:156-162. Hayashi S, Osawa T, Tohyama K. Comparative observations on corneas, with special reference to Bowman's layer and Descemet's membrane in mammals and amphibians. Journal of Morphology 2002;254:247-258. Håversen L, Ohlsson BG, Hahn-Zoric M, et al. Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-κB. Cellular Immunology 2002;220:83-95. Hemsley S, Cole N, Canfield P, et al. Protein microanalysis of animal tears. Research in Veterinary Science 2000;68:207-209. Hendrix DV, Ward DA, Barnhill MA. Effects of antibiotics on morphologic characteristics and migration of canine corneal epithelial cells in tissue culture. American Journal of Veterinary Research 2001;62:1664-1669. Hermeto LC, Rossi Rd, Pádua SB, et al. Comparative study between fibrin glue and platelet rich plasma in dogs skin grafts. Acta Cirurgica Brasileira 2012;27:789-794. Hori Y, Spurr-Michaud S, Russo CL, et al. Differential regulation of membrane-associated mucins in the human ocular surface epithelium. Investigative Ophthalmology & Visual Science 2004;45:114-122. Huang AJW, Tseng SCG. Corneal epithelial wound healing in the absence of limbal epithelium. Investigative Ophthalmology & Visual Science 1991;32:96-105. Huang N, Bethell D, Card C, et al. Bioactive recombinant human lactoferrin, derived from rice, stimulates mammalian cell growth. In Vitro Cellular & Developmental Biology-Animal 2008;44:464-471. Ibrahim E, Dean WH, Price N, et al. Perforating corneal ulceration in a patient with lung metastatic adenocarcinoma treated with gefitinib: a case report. Case Reports in Ophthalmological Medicine 2012;2012:379132. Imanishi J, Kamiyama K, Iguchi I, et al. Growth factors: importance in wound healing and maintenance of transparency of the cornea. Progress in Retinal and Eye Research 2000;19:113-129. Ikadai H, Tanaka T, Shibahara N, et al. Inhibitory effect of lactoferrin on in vitro growth of Babesia caballi. The American Journal of Tropical Medicine and Hygiene 2005;73:710-712. Iguchi I, Kamiyama K, Wang X, et al. Enhancing effect of platelet-derived growth factors on migration of corneal endothelial cells. Cornea 1995;14:365-371. Ishii K, Takamura N, Shinohara M, et al. Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months. Hepatology Research 2003;25:226-233. Janicijevic-Petrovic MA, Petrovic M, Vujic D, et al. Autologous serum eye drops for post-chemical injuries and corneal epithelial defects. Macedonian Journal of Medical Sciences 2013;6:383-387. Jensen TB, Rahbek O, Overgaard S, et al. Platelet rich plasma and fresh frozen bone allograft as enhancement of implant fixation. An experimental study in dogs. Journal of orthopaedic research 2004;22:653-658. Jenssen H, Hancock REW. Antimicrobial properties of lactoferrin. Biochimie 2009;91:19-29. Jester JV, Moller-Pedersen T, Huang J, et al. The cellular basis of corneal transparency: evidence for 'corneal crystallins'. Journal of Cell Science 1999;112:613-622. Jonasch E, Stadler WM, Bukowski RM, et al. Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Cancer 2008;113:72-77. Joyce NC. Proliferative capacity of the corneal endothelium. Progress in Retinal and Eye Research 2003;22:359-389. Kaito M, Iwasa M, Fujita N, et al. Effect of lactoferrin in patients with chronic hepatitis C: combination therapy with interferon and ribavirin. Journal of Gastroenterology and Hepatology 2007;22:1894-1897. Kaux JF, Le Goff C, Renouf J, et al. Comparison of the platelet concentrations obtained in platelet-rich plasma (PRP) between the GPS™ Ⅱ and GPS™ Ⅲsystems. Pathologie Biologie 2011;59:275-277. Kawakami H, Sugioka K, Yonesaka K, et al. Human epidermal growth factor eyedrops for cetuximab-related filamentary keratitis. Journal of Clinical Oncology 2011;29:e678-e679. Keijser S, Jager MJ, Dogterom-Ballering HCM, et al. Lactoferrin Glu561Asp polymorphism is associated with susceptibility to herpes simplex keratitis. Experimental Eye Research 2008;86:105-109. Kelly NE, Wendel RT. Vitreous surgery for idiopathic macular holes: results of a pilot study. Archives of Ophthalmology 1991;109:654-659. Kelly RJ, Giaccone G. The role of talactoferrin alfa in the treatment of non-small cell lung cancer. Expert Opinion on Biological Therapy 2010;10:1379-1386. Khaksar E, Aldavood SJ, Abedi GR, et al. The effect of sub-conjunctival platelet-rich plasma in combination with topical acetylcysteine on corneal alkali burn ulcer in rabbits. Comparative Clinical Pathology 2013;22:107-112. Khokhar S, Natung T, Sony P, et al. Amniotic membrane transplantation in refractory neurotrophic corneal ulcers: a randomized, controlled clinical trial. Cornea 2005;24:654-660. Kijlstra A, Jeurissen SHM, Koning KM. Lactoferrin levels in normal human tears. British Journal of Ophthalmology 1983;67:199-202. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Survey of Ophthalmology 2010;55:108-133. Kim KM, Shin YT, Kim HK. Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis. Japanese Journal of Ophthalmology 2012;56:544-550. Klenkler B, Sheardown H. Growth factors in the anterior segment: role in tissue maintenance, wound healing and ocular pathology. Experimental Eye Research 2004;79:677-688. Ko CL, Chen WC, Chen JC, et al. Properties of osteoconductive biomaterials: calcium phosphate cement with different ratios of platelet-rich plasma as identifiers. Materials Science and Engineering C 2013;33:3537-3544. Kobayashi T, Shiraishi A, Hara Y, et al. Stromal-epithelial interaction study: the effect of corneal epithelial cells on growth factor expression in stromal cells using organotypic culture model. Experimental Eye Research 2015;135:109-117. Koffler BH. Autologous serum therapy of the ocular surface with novel delivery by platelet concentrate gel. The Ocular Surface 2006;4:188-195. Kozu T, Iinuma G, Ohashi Y, et al. Effect of orally administered bovine lactoferrin on the growth of adenomatous colorectal polyps in a randomized, placebo-controlled clinical trial. Cancer Prevention Research 2009;2:975-983. Kuipers M, de Vries H, Eikelboom M, et al. Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates. Antimicrobial Agents and Chemotherapy 1999;43:2635-2641. Kumar R, Parmar I, Chhillar N, et al. Tear lactoferrin concentration during postoperative ocular inflammation in cataract surgery. Acta Ophthalmologica Scandinavica 1997;75:142-144. Kuwata H, Yamauchi K, Teraguchi S, et al. Functional fragments of ingested lactoferrin are resistant to proteolytic degradation in the gastrointestinal tract of adult rats. The Journal of Nutrition 2001;131:2121-2127. Lam H, Bleiden L, de Paiva CS, et al. Tear cytokine profiles in dysfunctional tear syndrome. American Journal of Ophthalmology 2009;147:198-205. Lambiase A, Rama P, Bonini S, et al. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. New England Journal of Medicine 1998;338:1174-1180. Lee WJ, Farmer JL, Hilty M, et al. The protective effects of lactoferrin feeding against endotoxin lethal shock in germfree piglets. Infection and Immunity 1998;66:1421-1426. Legrand D, Mazurier J, Maes P, et al. Inhibition of the specific binding of human lactotransferrin to human peripheral-blood phytohaemagglutinin-stimulated lymphocytes by fluorescein labelling and location of the binding site. The Biochemical Journal 1991;276:733-738. Legrand D, Elass E, Carpentier M, et al. Lactoferrin: a modulator of immune and inflammatory responses. Cellular and Molecular Life Sciences 2005;62:2549-2559. Legrand D, Mazurier J. A critical review of the roles of host lactoferrin in immunity. Biometals 2010;23:365-376. Ledbetter EC, Munger RJ, Ring RD, et al. Efficacy of two chondroitin sulfate ophthalmic solutions in the therapy of spontaneous chronic corneal epithelial defects and ulcerative keratitis associated with bullous keratopathy in dogs. Veterinary Ophthalmology 2006;9:77-87. Ledbetter EC, Gilger BC. Diseases and surgery of the canine cornea and sclera. In: Gelatt KN, Gilger BC, Kern TJ, eds. Veterinary Ophthalmology. 5th ed. Iowa: John Wiley & Sons Inc., 2013;976-1049. Lei H, Gui L, Xiao R. The effect of anticoagulants on the quality and biological efficacy of platelet-rich plasma. Clinical Biochemistry 2009;42:1452-1460. Leitch EC, Willcox MD. Synergic antistaphylococcal properties of lactoferrin and lysozyme. Journal of Medical Microbiology 1998;47:837-842. Leitch EC, Willcox MD. Elucidation of the antistaphylococcal action of lactoferrin and lysozyme. Journal of Medical Microbiology 1999;48:867-871. Leitner GC, Gruber R, Neumüller J, et al. Platelet content and growth factor release in platelet‐rich plasma: a comparison of four different systems. Vox Sanguinis 2006;91:135-139. Lekhanont K, Jongkhajornpong P, Choubtum L, et al. Topical 100% serum eye drops for treating corneal epithelial defect after ocular surgery. BioMed Research International 2013;2013:521315. Lemp MA. Advances in understanding and managing dry eye disease. American Journal of Ophthalmology 2008;146:350-356. León-Sicairos N, López-Soto F, Reyes-López M, et al. Amoebicidal activity of milk, apo-lactoferrin, sIgA and lysozyme. Clinical Medicine & Research 2006;4:106-113. Levay PF, Viljoen M. Lactoferrin: a general review. Haematologica 1995;80:252-267. Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea 2001;20:1-13. Li DQ, Tseng SC. Differential regulation of keratinocyte growth factor and hepatocyte growth factor/scatter factor by different cytokines in human corneal and limbal fibroblasts. Journal of Cellular Physiology 1997;172:361-372. Li Z, Rumbaut RE, Burns AR, et al. Platelet response to corneal abrasion is necessary for acute inflammation and efficient re-epithelialization. Investigative Ophthalmology & Visual science 2006;47:4794-4802. Li Z, Burns AR, Rumbaut RE, et al. γδ T cells are necessary for platelet and neutrophil accumulation in limbal vessels and efficient epithelial repair after corneal abrasion. The American Journal of Pathology 2007;171:838-845. Liu L, Hartwig D, Harloff S, et al. An optimised protocol for the production of autologous serum eyedrops. Graefe's Archive for Clinical and Experimental Ophthalmology 2005;243:706-714. Liu L, Hartwig D, Harloff S, et al. Corneal epitheliotrophic capacity of three different blood-derived preparations. Investigative Ophthalmology and Visual Science 2006;47:2438-2444. López-García JS, García-Lozano I, Rivas L, et al. Use of autologous serum in ophthalmic practice. Archivos de la Sociedad Espanola de Oftalmologia 2007;82:9-20. López-Plandolit S, Morales MC, Freire V, et al. Plasma rich in growth factors as a therapeutic agent for persistent corneal epithelial defects. Cornea 2010;29:843-848. Lu L, Reinach PS, Kao WWY. Corneal epithelial wound healing. Experimental Biology and Medicine 2001;226:653-664. Lupetti A, Paulusma-Annema A, Welling MM, et al. Synergistic activity of the N-terminal peptide of human lactoferrin and fluconazole against Candida species. Antimicrobial Agents and Chemotherapy 2003;47:262-267. Lyons TE, Miller MS, Serena T, et al. Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. The American Journal of Surgery 2007;193:49-54. Machnicki M, Zimecki M, Zagulski T. Lactoferrin regulates the release of tumour necrosis factor alpha and interleukin 6 in vivo. International Journal of Experimental Pathology 1993;74:433-439. Maddula S, Davis DK, Maddula S, et al. Horizons in therapy for corneal angiogenesis. Ophthalmology 2011;118:591-599. Maggs DJ. Ocular pharmacology and therapeutics. In: Maggs DJ, Miller PE, Ofri R, eds. Slatter's Fundamentals of Veterinary Ophthalmology. 5th ed. Philadelphia: Elsevier Inc., 2013a;27-59. Maggs DJ. Cornea and sclera. In: Maggs DJ, Miller PE, Ofri R, eds. Slatter's Fundamentals of Veterinary Ophthalmology. 5th ed. Philadelphia: Elsevier Inc., 2013b;184-219. Maltseva O, Folger P, Zekaria D, et al. Fibroblast growth factor reversal of the corneal myofibroblast phenotype. Investigative Ophthalmology & Visual Science 2001;42:2490-2495. Mantelli F, Massaro‐Giordano M, Macchi I, et al. The cellular mechanisms of dry eye: from pathogenesis to treatment. Journal of Cellular Physiology 2013;228:2253-2256. Marfurt CF, Murphy CJ, Florczak JL. Morphology and neurochemistry of canine corneal innervation. Investigative Ophthalmology & Visual Science 2001;42:2242-2251. Marquez-de-Aracena R, Montero-de-Espinosa I, Munoz M, et al. Subconjunctival application of plasma platelet concentrate in the treatment of ocular burns. Preliminary results. Archivos de la Sociedad Española de Oftalmología 2007;82:475-482. Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dentistry 2001;10:225-228. Marx RE, Carlson ER, Eichstaedt RM, et al. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics 1998;85:638-646. Matsuda M, Ubels JL, Edelhauser HF. A larger corneal epithelial wound closes at a faster rate. Investigative Ophthalmology & Visual Science 1985;26:897-900. Massingale ML, Li X, Vallabhajosyula M, et al. Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea 2009;28:1023-1027. Metz‐Boutigue MH, Jollès J, Mazurier J, et al. Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins. European Journal of Biochemistry 1984;145:659-676. Miller PE. Lacrimal system. In: Maggs DJ, Miller PE, Ofri R, eds. Slatter's Fundamentals of Veterinary Ophthalmology. 5th ed. Philadelphia: Elsevier Inc., 2013a;165-183. Miller PE. Uvea. In: Maggs DJ, Miller PE, Ofri R, eds. Slatter's Fundamentals of Veterinary Ophthalmology. 5th ed. Philadelphia: Elsevier Inc., 2013b;220-246. Mishra A, Woodall J, Vieira A. Treatment of tendon and muscle using platelet-rich plasma. Clinics in Sports Medicine 2009;28:113-125. Miyauchi H, Hashimoto S, Nakajima M, et al. Bovine lactoferrin stimulates the phagocytic activity of human neutrophils: identification of its active domain. Cellular Immunology 1998;187:34-37. Mohan RR, Mohan RR, Wilson SE. Discoidin domain receptor (DDR) 1 and 2: collagen-activated tyrosine kinase receptors in the cornea. Experimental Eye Research 2001;72:87-92. Moreira LB, Kasetsuwan N, Sanchez D, et al. Toxicity of topical anesthetic agents to human keratocytes in vivo. Journal of Cataract & Refractive Surgery 1999;25:975-980. Murphy CJ, Marfurt CF, McDermott A, et al. Spontaneous chronic corneal epithelial defects (SCCED) in dogs: clinical features, innervation, and effect of topical SP, with or without IGF-1. Investigative Ophthalmology & Visual Science 2001;42:2252-2261. Müller LJ, Marfurt CF, Kruse F, et al. Corneal nerves: structure, contents and function. Experimental Eye Research 2003;76:521-542. Na YJ, Han SB, Kang JS, et al. Lactoferrin works as a new LPS-binding protein in inflammatory activation of macrophages. International Immunopharmacology 2004;4:1187-1199. Nagano T, Nakamura M, Nakata K, et al. Effects of substance P and IGF-1 in corneal epithelial barrier function and wound healing in a rat model of neurotrophic keratopathy. Cornea 2003;44:3810-3815. Nakamura M, Sato N, Chikama T, et al. Fibronectin facilitates corneal epithelial wound healing in diabetic rats. Experimental Eye Research 1997;64:355-359. Nakamura Y, Sotozono C, Kinoshita S. Inflammatory cytokines in normal human tears. Current Eye Research 1998;17:673-676. Nakamura M, Kawahara M, Nakata K, et al. Restoration of corneal epithelial barrier function and wound healing by substance P and IGF-1 in rats with capsaicin-induced neurotrophic keratopathy. Investigative Ophthalmology & Visual Science 2003;44:2937-2940. Nather A, Wong KL, David V, et al. Allografts with autogenous platelet-rich plasma for tibial defect reconstruction: a rabbit study. Journal of Orthopaedic Surgery 2012;20:375-380. Nishida T, Ohashi Y, Awata T, et al. Fibronectin: a new therapy for corneal trophic ulcer. Archives of Ophthalmology 1983;101:1046-1048. Nishida T, Chikama TI, Sawa M, et al. Differential contributions of impaired corneal sensitivity and reduced tear secretion to corneal epithelial disorders. Japanese Journal of Ophthalmology 2012;56:20-25. Noble BA, Loh RS, MacLennan S, et al. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. British Journal of Ophthalmology 2004;88:647-652. Odell EW, Sarra R, Foxworthy M, et al. Antibacterial activity of peptides homologous to a loop region in human lactoferrin. FEBS Letters 1996;382:175-178. Okutomi T, Abe S, Tansho S, et al. Augmented inhibition of growth of Candida albicans by neutrophils in the presence of lactoferrin. FEMS Immunology & Medical Microbiology 1997;18:105-112. Ollivier FJ, Brooks DE, Kallberg ME, et al. Evaluation of various compounds to inhibit activity of matrix metalloproteinases in the tear film of horses with ulcerative keratitis. American Journal of Veterinary Research 2003;64:1081-1087. Oo TZ, Cole N, Garthwaite L, et al. Evaluation of synergistic activity of bovine lactoferricin with antibiotics in corneal infection. Journal of Antimicrobial Chemotherapy 2010;65:1243-1251. Pallua N, Wolter T, Markowicz M. Platelet-rich plasma in burns. Burns 2010;36:4-8. Panda A, Jain M, Vanathi M, et al. Topical autologous platelet-rich plasma eyedrops for acute corneal chemical injury. Cornea 2012;31:989-993. Park J, Lee KM, Zhou H, et al. Community practice patterns for bacterial corneal ulcer evaluation and treatment. Eye & Contact Lens 2015;41:12-18. Pastor JC, Calonge M. Epidermal growth factor and corneal wound healing: a multicenter study. Cornea 1992;11:311-314. Pattamatta U, Willcox M, Stapleton F, et al. Bovine lactoferrin stimulates human corneal epithelial alkali wound healing in vitro. Investigative Ophthalmology & Visual Science 2009;50:1636-1643. Pattamatta U, Willcox M, Stapleton F, et al. Bovine lactoferrin promotes corneal wound healing and suppresses IL-1 expression in alkali wounded mouse cornea. Current Eye Research 2013;38:1110-1117. Phan TM, Foster CS, Shaw CD, et al. Topical fibronectin in an alkali burn model of corneal ulceration in rabbits. Archives of Ophthalmology 1991;109:414-419. Pietramaggiori G, Scherer SS, Mathews JC, et al. Quiescent platelets stimulate angiogenesis and diabetic wound repair. Journal of Surgical Research 2010;160:169-177. Poon AC, Geerling G, Dart JK, et al. Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. British Journal of Ophthalmology 2001;85:1188-1197. Powell DM, Chang E, Farrior EH. Recovery from deep-plane rhytidectomy following unilateral wound treatment with autologous platelet gel: a pilot study. Archives of Facial Plastic Surgery 2001;3:245-250. Puddu P, Valenti P, Gessani S. Immunomodulatory effects of lactoferrin on antigen presenting cells. Biochimie 2009;91:11-18. Ramalingam S, Crawford J, Chang A, et al. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). Annals of Oncology 2013;24:2875-2880. Regnier A. Drug delivery and pharmacokinetics. In: Gelatt KN, Gilger BC, Kern TJ, eds. Veterinary Ophthalmology. 5th ed. Iowa: John Wiley & Sons Inc., 2013;351-380. Rolando M, Zierhut M. The ocular surface and tear film and their dysfunction in dry eye disease. Survey of Ophthalmology 2001;45:S203-S210. Sakamoto T, Ueno H, Sonoda K, et al. Blockade of TGF-beta by in vivo gene transfer of a soluble TGF-beta type Ⅱ receptor in the muscle inhibits corneal opacification, edema and angiogenesis. Gene Therapy 2000;7:1915-1924. Sammartino G, Tia M, Marenzi G, et al. Use of autologous platelet-rich plasma (PRP) in periodontal defect treatment after extraction of impacted mandibular third molars. Journal of Oral and Maxillofacial Surgery 2005;63:766-770. Samuelson DA. Ophthalmic anatomy. In: Gelatt KN, Gilger BC, Kern TJ, eds. Veterinary Ophthalmology. 5th ed. Iowa: John Wiley & Sons Inc., 2013;39-170. Sandri G, Bonferoni MC, Rossi S, et al. Thermosensitive eyedrops containing platelet lysate for the treatment of corneal ulcers. International Journal of Pharmaceutics 2012;426:1-6. Santagati MG, La Terra Mulè S, Amico C, et al. Lactoferrin expression by bovine ocular surface epithelia: a primary cell culture model to study lactoferrin gene promoter activity. Ophthalmic Research 2005;37:270-278. Schrader S, Wedel T, Moll R, et al. Combination of serum eye drops with hydrogel bandage contact lenses in the treatment of persistent epithelial defects. Graefe's Archive for Clinical and Experimental Ophthalmology 2006;244:1345-1349. Schultz CL, Morck DW. Contact lenses as a drug delivery device for epidermal growth factor in the treatment of ocular wounds. Clinical and Experimental Optometry 2010;93:61-65. Semeraro F, Forbice E, Braga O, et al. Evaluation of the efficacy of 50% autologous serum eye drops in different ocular surface pathologies. BioMed Research International 2014;2014:826970. Sfeir RM, Dubarry M, Boyaka PN, et al. The mode of oral bovine lactoferrin administration influences mucosal and systemic immune responses in mice. The Journal of Nutrition 2004;134:403-409. Shamsi FA, Chen Z, Liang J, et al. Analysis and comparison of proteomic profiles of tear fluid from human, cow, sheep, and camel eyes. Investigative Ophthalmology & Visual Science 2011;52:9156-9165. Shau H, Kim A, Golub SH. Modulation of natural killer and lymphokine-activated killer cell cytotoxicity by lactoferrin. Journal of Leukocyte Biology 1992;51:343-349. Shimazaki K, Tazume T, Uji K, et al. Properties of a heparin-binding peptide derived from bovine lactoferrin. Journal of Dairy Science 1998;81:2841-2849. Shimmura S, Suematsu M, Shimoyama M, et al. Subthreshold UV radiation-induced peroxide formation in cultured corneal epithelial cells: the protective effects of lactoferrin. Experimental Eye Research 1996;63:519-526. Shimmura S, Shimoyama M, Hojo M, et al. Reoxygenation injury in a cultured corneal epithelial cell line protected by the uptake of lactoferrin. Investigative Ophthalmology & Visual Science 1998;39:1346-1351. Singh PK, Parsek MR, Greenberg EP, et al. A component of innate immunity prevents bacterial biofilm development. Nature 2002;417:552-555. Smith RE, Sadun AA. Clearing the cornea with nerve growth factor. The New England Journal of Medicine 1998;338:1222-1223. Sommeling C, Heyneman A, Hoeksema H, et al. The use of platelet-rich plasma in plastic surgery: a systematic review. Journal of Plastic, Reconstructive & Aesthetic Surgery 2013;66:301-311. Sorimachi K, Akimoto K, Hattori Y, et al. Activation of macrophages by lactoferrin: secretion of TNF‐α, IL‐8 and NO. Biochemistry and Molecular Biology International 1997;43:79-87. Steele C. Corneal wound healing: a review. Optometry Today 1999;24:28-32. Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Archives of Ophthalmology 2012;130:90-100. Stiles J, Honda CN, Krohne SG, et al. Effect of topical administration of 1% morphine sulfate solution on signs of pain and corneal wound healing in dogs. American Journal of Veterinary Research 2003;64:813-818. Strubbe DT, Brooks DE, Schultz GS, et al. Evaluation of tear film proteinases in horses with ulcerative keratitis. Veterinary Ophthalmology 2000;3:111-119. Sun Y, Feng Y, Zhang CQ, et al. The regenerative effect of platelet-rich plasma on healing in large osteochondral defects. International Orthopaedics 2010;34:589-597. Sun R, Hamilton RC, Gimbel HV. Comparison of 4 topical anesthetic agents for effect and corneal toxicity in rabbits. Journal of Cataract & Refractive Surgery 1999;25:1232-1236. Suzuki T, Kinoshita Y, Tachibana M, et al. Expression of sex steroid hormone receptors in human cornea. Current Eye Research 2001;22:28-33. Tachibana M, Kasukabe T, Kobayashi Y, et al. Expression of estrogen receptor α and β in the mouse cornea. Investigative Ophthalmology & Visual Science 2000;41:668-670. Takayama Y, Aoki R. Roles of lactoferrin on skin wound healing. Biochemistry and Cell Biology 2011;90:497-503. Takayama Y, Mizumachi K. Effects of lactoferrin on collagen gel contractile activity and myosin light chain phosphorylation in human fibroblasts. FEBS Letters 2001;508:111-116. Tan MH, Bryars J, Moore J. Use of nerve growth factor to treat congenital neurotrophic corneal ulceration. Cornea 2006;25:352-355. Tang L, Cui T, Wu JJ, et al. A rice‐derived recombinant human lactoferrin stimulates fibroblast proliferation, migration, and sustains cell survival. Wound Repair and Regeneration 2010a;18:123-131. Tang L, Wu JJ, Ma Q, et al. Human lactoferrin stimulates skin keratinocyte function and wound re‐epithelialization. British Journal of Dermatology 2010b;163:38-47. Teraguchi S, Shin K, Ozawa K, et al. Bacteriostatic effect of orally administered bovine lactoferrin on proliferation of Clostridium species in the gut of mice fed bovine milk. Applied and Environmental Microbiology 1995;61:501-506. Tolar EL, Hendrix DV, Rohrbach BW, et al. Evaluation of clinical characteristics and bacterial isolates in dogs with bacterial keratitis: 97 cases (1993-2003). Journal of the American Veterinary Medical Association 2006;228:80-85. Trif M, Guillen C, Vaughan DM, et al. Liposomes as possible carriers for lactoferrin in the local treatment of inflammatory diseases. Experimental Biology and Medicine 2001;226:559-564. Tsai P, Evans J, Green K, et al. Proteomic analysis of human meibomian gland secretions. British Journal of Ophthalmology 2006;90:372-377. Tsubota K, Goto E, Fujita H, et al. Treatment of dry eye by autologous serum application in Sjögren's syndrome. British Journal of Ophthalmology 1999a;83: 390-395. Tsubota K, Goto E, Shimmura S, et al. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology 1999b;106:1984-1989. Tsuda H, Kozu T, Iinuma G, et al. Cancer prevention by bovine lactoferrin: from animal studies to human trial. Biometals 2010;23:399-409. Tuominen IS, Tervo TM, Teppo AM, et al. Human tear fluid PDGF-BB, TNF-α and TGF-β1 vs corneal haze and regeneration of corneal epithelium and subbasal nerve plexus after PRK. Experimental Eye Research 2001;72:631-641. Tursi A, Elisei W, Brandimarte G, et al. Effect of lactoferrin supplementation on the effectiveness and tolerability of a 7-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection. Medical Science Monitor 2007;13:CR187-CR190. Uchino E, Sonoda S, Nakao K, et al. Alteration of tear cytokine balance by eye closure: analysis by multicytokine assay. Graefe's Archive for Clinical and Experimental Ophthalmology 2006;244:747-749. Vanore M, Chahory S, Payen G, et al. Surgical repair of deep melting ulcers with porcine small intestinal submucosa (SIS) graft in dogs and cats. Veterinary Ophthalmology 2007;10:93-99. van der Strate BWA, Beljaars L, Molema G, et al. Antiviral activities of lactoferrin. Antiviral Research 2001;52:225-239. Varadhachary A, Wolf JS, Petrak K, et al. Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. International Journal of Cancer 2004;111:398-403. Vesaluoma M, Teppo AM, Grönhagen-Riska C, et al. Platelet-derived growth factor-BB (PDGF-BB) in tear fluid: a potential modulator of corneal wound healing following photorefractive keratectomy. Current Eye Research 1997;16:825-831. Viani RM, Gutteberg TJ, Lathey JL, et al. Lactoferrin inhibits HIV-1 replication in vitro and exhibits synergy when combined with zidovudine. Aids 1999;13:1273-1274. Wakabayashi H, Abe S, Okutomi T, et al. Cooperative anti‐Candida effects of lactoferrin or its peptides in combination with azole antifungal agents. Microbiology and Immunology 1996;40:821-825. Wakabayashi H, Abe S, Teraguchi S, et al. Inhibition of hyphal growth of azole-resistant strains of Candida albicans by triazole antifungal agents in the presence of lactoferrin-related compounds. Antimicrobial Agents and Chemotherapy 1998;42:1587-1591. Wang SB, Hu KM, Seamon KJ, et al. Estrogen negatively regulates epithelial wound healing and protective lipid mediator circuits in the cornea. The Journal of the Federation of American Societies for Experimental Biology 2012;26:1506-1516. Wang L, Pan Q, Xue Q, et al. Evaluation of matrix metalloproteinase concentrations in precorneal tear film from dogs with Pseudomonas aeruginosa-associated keratitis. American Journal of Veterinary Research 2008;69:1341-1345. Wang L, Wu X, Shi T, et al. Epidermal growth factor (EGF)-induced corneal epithelial wound healing through nuclear factor κB subtype-regulated CCCTC binding factor (CTCF) activation. Journal of Biological Chemistry 2013;288:24363-24371. Wang X, Wu Q. Normal corneal thickness measurements in pigmented rabbits using spectral‐domain anterior segment optical coherence tomography. Veterinary Ophthalmology 2013;16:130-134. Ward PP, Mendoza-Meneses M, Cunningham GA, et al. Iron status in mice carrying a targeted disruption of lactoferrin. Molecular and Cellular Biology 2003;23:178-185. Ward PP, Conneely OM. Lactoferrin: role in iron homeostasis and host defense against microbial infection. Biometals 2004;17:203-208. Watanabe K, Nakagawa S, Nishida T. Stimulatory effects of fibronectin and EGF on migration of corneal epithelial cells. Investigative Ophthalmology & Visual Science 1987;28:205-211. West-Mays JA, Dwivedi DJ. The keratocyte: corneal stromal cell with variable repair phenotypes. The International Journal of Biochemistry & Cell Biology 2006;38:1625-1631. Williams TJ, Schneider RP, Willcox MD. The effect of protein-coated contact lenses on the adhesion and viability of gram negative bacteria. Current Eye Research 2003;27:227-235. Williams KK, Shepard AR, Rice RL, et al. Corneal wound healing in New Zealand White rabbits following anterior keratectomy and treatment with moxifloxacin ophthalmic solution 0.5% or gatifloxacin ophthalmic solution 0.3%. Journal of Ocular Pharmacology and Therapeutics 2007;23:517-526. Williams DL. Immunopathogenesis of keratoconjunctivitis sicca in the dog. Veterinary Clinics of North America: Small Animal Practice 2008;38:251-268. Wilson SE, Schultz GS, Chegini N, et al. Epidermal growth factor, transforming growth factor alpha, transforming growth factor beta, acidic fibroblast growth factor, basic fibroblast growth factor, and interleukin-1 proteins in the cornea. Experimental Eye Research 1994;59:63-72. Wilson SE, Chen L, Mohan RR, et al. Expression of HGF, KGF, EGF and receptor messenger RNAs following corneal epithelial wounding. Experimental Eye Research 1999a;68:377-397. Wilson SE, Liang Q, Kim WJ. Lacrimal gland HGF, KGF, and EGF mRNA levels increase after corneal epithelial wounding. Investigative Ophthalmology & Visual Science 1999b;40:2185-2190. Wilson SE, Liu JJ, Mohan RR. Stromal-epithelial interactions in the cornea. Progress in Retinal and Eye Research 1999c;18:293-309. Wilson SE, Hong JW. Bowman's layer structure and function: critical or dispensable to corneal function? A hypothesis. Cornea 2000;19:417-420. Wilson SE, Mohan RR, Mohan RR, et al. The corneal wound healing response: cytokine-mediated interaction of the epithelium, stroma, and inflammatory cells. Progress in Retinal and Eye Research 2001;20:625-637. Wilson SE, Chaurasia SS, Medeiros FW. Apoptosis in the initiation, modulation and termination of the corneal wound healing response. Experimental Eye Research 2007;85:305-311. Wipperman JL, Dorsch JN. Evaluation and management of corneal abrasions. American Family Physician 2013;87:114-120. Wolf JS, Li G, Varadhachary A, et al. Oral lactoferrin results in T cell-dependent tumor inhibition of head and neck squamous cell carcinoma in vivo. Clinical Cancer Research 2007;13:1601-1610. Yamada C, King KE, Ness PM. Autologous serum eyedrops: literature review and implications for transfusion medicine specialists. Transfusion 2008;48:1245-1255. Yamaguchi R, Terashima H, Yoneyama S, et al. Effects of platelet-rich plasma on intestinal anastomotic healing in rats: PRP concentration is a key factor. Journal of Surgical Research 2012;173:258-266. Yanwei L, Wei Z, Yu Z. The relationship between dry eye and lactoferrin levels in tears. Asian Biomedicine 2012;6:81-85. Yoon KC, You IC, Im SK, et al. Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis. Ophthalmology 2007;114:1637-1642. Young A, Cheng A, Ng H, et al. The use of autologous serum tears in persistent corneal epithelial defects. Eye 2004;18:609-614. Yu FSX, Yin J, Xu K, et al. Growth factors and corneal epithelial wound healing. Brain Research Bulletin 2010;81:229-235. Zarember KA, Sugui JA, Chang YC, et al. Human polymorphonuclear leukocytes inhibit Aspergillus fumigatus conidial growth by lactoferrin-mediated iron depletion. The Journal of Immunology 2007;178:6367-6373. Zhang GH, Mann DM, Tsai CM. Neutralization of endotoxin in vitro and in vivo by a human lactoferrin-derived peptide. Infection and Immunity 1999;67:1353-1358. Zhou L, Beuerman RW, Barathi A, et al. Analysis of rabbit tear proteins by high‐pressure liquid chromatography/electrospray ionization mass spectrometry. Rapid Communications in Mass Spectrometry 2003;17:401-412. Zhou L, Beuerman RW. Tear analysis in ocular surface diseases. Progress in Retinal and Eye research 2012;31:527-550. Zieske JD, Takahashi H, Hutcheon AE, et al. Activation of epidermal growth factor receptor during corneal epithelial migration. Investigative Ophthalmology and Visual Science 2000;41:1346-1355. Zimecki M, Mazurier J, Spik G, et al. Human lactoferrin induces phenotypic and functional changes in murine splenic B cells. Immunology 1995;86:122-127. Zuccotti GV, Vigano A, Borelli M, et al. Modulation of innate and adaptive immunity by lactoferrin in human immunodeficiency virus (HIV)-infected, antiretroviral therapy-naïve children. International Journal of Antimicrobial Agents 2007;29:353-355.
摘要: 角膜潰瘍起因於上皮受損過度或保護機制功能不足,為小動物臨床醫學常見疾病之一,治療原則為移除病因、預防繼發性細菌感染、緩解疼痛與發炎等症狀,以及促進角膜癒合。自體血清與血小板濃厚血漿眼藥水皆富含生長因子、細胞激素與其他能促進角膜癒合的物質,可用於治療角膜潰瘍,但因需抽取多量血液,於小動物臨床應用上有所限制。乳鐵蛋白存在於正常淚液中,除了能抑制病原微生物生長,亦可能具有降低炎症反應與促進角膜上皮癒合之功能。本研究目的為評估並比較商品化乳鐵蛋白、血小板濃厚血漿眼藥水與自體血清眼藥水對於促進角膜上皮癒合之療效。實驗對象為20隻紐西蘭白兔,共40個眼睛,將其分為8組,實驗一除了控制組外,於誘導角膜上皮缺損後分別給予0.5%、1%、2%乳鐵蛋白眼藥水、10%血小板濃厚血漿眼藥水或50%自體血清眼藥水,每日2次,每組各6個眼睛;實驗二則增加點藥頻率至每日10次,分別給予0.5%乳鐵蛋白或10%血小板濃厚血漿眼藥水,每組各2個眼睛。於誘導角膜上皮缺損後第 0、4、8、16、20、24、28、32、40、44、48、52、56、64、68、72、76、80、88、92、96、100 小時觀察其臨床症狀與角膜上皮缺損面積,並於實驗結束後進行角膜組織病理學檢查與眼藥水微生物學檢查;於100小時內,共38個角膜(95%)達完全癒合,各組角膜上皮缺損面積、癒合面積、癒合時間、平均癒合速率皆無顯著差異(p >0.05),組織病理學檢查可見各組皆癒合良好,且所有眼藥水皆未受到細菌汙染。本實驗結果顯示,使用 0.5%、1%、2%乳鐵蛋白、10%血小板濃厚血漿或50%自體血清眼藥水,皆無顯著促進角膜上皮癒合或改善臨床症狀之療效。
Corneal ulcers usually result from excessive corneal epithelial injury or lack of protective mechanisms, and it is a common disease in small animal ophthalmology. The treatment protocol is to identify and remove the pathogenic cause, prevent secondary infection, relieve pain, control the inflammatory process, and promote corneal healing. Autologous serum and platelet-rich plasma (PRP) eyedrops are blood derivatives containing cytokine, growth factors and other components which may accelerate corneal healing. Both eyedrops are effective in the treatment of corneal ulceration; however, the clinical application in small animal ophthalmology is often limited by the requirement of a considerable amount of blood to be drawn, which is not feasible in some patients. Lactoferrin is a glycoprotein found in normal tears, besides the antimicrobial activity, it may also harbor the ability to suppress inflammation and promote corneal healing. The purpose of this study is to evaluate and compare the efficacy of topical lactoferrin, platelet-rich plasma and autologous serum in corneal epithelial wound healing. Twenty New Zealand albino rabbits (40 eyes) were used in this study and divided into eight groups. In experiment 1, except for the control group, the eyes were treated with topical 0.5%, 1%, or 2% lactoferrin, 10% PRP, or 50% autologous serum twice a day, respectively (n=6 in each group). In experiment 2, the eyes were treated with topical 0.5% lactoferrin or 10% PRP ten times a day, respectively (n=2 in each group). Clinical signs and corneal epithelial defect area were recorded at 0, 4, 8, 16, 20, 24, 28, 32, 40, 44, 48, 52, 56, 64, 68, 72, 76, 80, 88, 92, 96 and 100 hours after induction of corneal epithelial defect. At 100 hours post-injury, the corneas were excised for histopathological examination, and the eyedrops were cultured for sterility analysis. Thirty eight corneas (95%) were completely healed within 100 hours post-injury. There was no statistically difference in the corneal epithelial defect area, healing area, complete heal time, and mean healing rate among the groups. Histopathological examination of the corneas showed normal healing features. All of the eyedrops remain sterile after 100 hours of storage. Treatment with topical 0.5%, 1%, or 2% lactoferrin, 10% PRP, or 50% autologous serum did not reveal the efficacy of accelerating corneal epithelial healing or improving clinical signs in this study.
URI: http://hdl.handle.net/11455/93004
其他識別: U0005-0608201515425400
文章公開時間: 2018-08-21
Appears in Collections:獸醫學系所

文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.